Selected research
Market Outlook & Growth Opportunities
Global AI Medical Imaging Software for Lung Diseases Market Outlook and Growth Opportunities 2026
Market perspective
The global AI Medical Imaging Software for Lung Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for AI Medical Imaging Software for Lung Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for AI Medical Imaging Software for Lung Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for AI Medical Imaging Software for Lung Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the AI Medical Imaging Software for Lung Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the AI Medical Imaging Software for Lung Diseases market include Riverain Technologies, BioMind, Fosun Aitrox, Huiying Medical, United-Imaging, Deepwise, Shukun Technology, VoxelCloud and Infervision Medical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global AI Medical Imaging Software for Lung Diseases market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of AI Medical Imaging Software for Lung Diseases and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents AI Medical Imaging Software for Lung Diseases revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Medical Imaging Software for Lung Diseases market.
AI Medical Imaging Software for Lung Diseases Segment by Company
Riverain Technologies
BioMind
Fosun Aitrox
Huiying Medical
United-Imaging
Deepwise
Shukun Technology
VoxelCloud
Infervision Medical
Siemens
Yizhun Intelligent
AI Medical Imaging Software for Lung Diseases Segment by Type
Pulmonary Nodules
Pneumonia
Other
AI Medical Imaging Software for Lung Diseases Segment by Application
Hospital
Clinic
AI Medical Imaging Software for Lung Diseases Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global AI Medical Imaging Software for Lung Diseases status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the AI Medical Imaging Software for Lung Diseases key companies, revenue, market share, and recent developments.
3. To split the AI Medical Imaging Software for Lung Diseases breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions AI Medical Imaging Software for Lung Diseases market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify AI Medical Imaging Software for Lung Diseases significant trends, drivers, influence factors in global and regions.
6. To analyze AI Medical Imaging Software for Lung Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Medical Imaging Software for Lung Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Medical Imaging Software for Lung Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Medical Imaging Software for Lung Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Medical Imaging Software for Lung Diseases industry.
Chapter 3: Detailed analysis of AI Medical Imaging Software for Lung Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of AI Medical Imaging Software for Lung Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of AI Medical Imaging Software for Lung Diseases in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Pulmonary Nodules
- Pneumonia
- Other
Applications
- Hospital
- Clinic
Companies covered
- Riverain Technologies
- BioMind
- Fosun Aitrox
- Huiying Medical
- United-Imaging
- Deepwise
- Shukun Technology
- VoxelCloud
- Infervision Medical
- Siemens
- Yizhun Intelligent
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global AI Medical Imaging Software for Lung Diseases Market Size, 2021 VS 2025 VS 2032
- 1.3 Global AI Medical Imaging Software for Lung Diseases Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 AI Medical Imaging Software for Lung Diseases Market Dynamics
- 2.1 AI Medical Imaging Software for Lung Diseases Industry Trends
- 2.2 AI Medical Imaging Software for Lung Diseases Industry Drivers
- 2.3 AI Medical Imaging Software for Lung Diseases Industry Opportunities and Challenges
- 2.4 AI Medical Imaging Software for Lung Diseases Industry Restraints
3 AI Medical Imaging Software for Lung Diseases Market by Company
- 3.1 Global AI Medical Imaging Software for Lung Diseases Company Revenue Ranking in 2025
- 3.2 Global AI Medical Imaging Software for Lung Diseases Revenue by Company (2021-2026)
- 3.3 Global AI Medical Imaging Software for Lung Diseases Company Ranking (2024-2026)
- 3.4 Global AI Medical Imaging Software for Lung Diseases Company Manufacturing Base and Headquarters
- 3.5 Global AI Medical Imaging Software for Lung Diseases Company Product Type and Application
- 3.6 Global AI Medical Imaging Software for Lung Diseases Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global AI Medical Imaging Software for Lung Diseases Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 AI Medical Imaging Software for Lung Diseases Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 AI Medical Imaging Software for Lung Diseases Market by Type
- 4.1 AI Medical Imaging Software for Lung Diseases Type Introduction
- 4.1.1 Pulmonary Nodules
- 4.1.2 Pneumonia
- 4.1.3 Other
- 4.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Type
- 4.2.1 Global AI Medical Imaging Software for Lung Diseases Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Type (2021-2032)
- 4.2.3 Global AI Medical Imaging Software for Lung Diseases Sales Value Share by Type (2021-2032)
5 AI Medical Imaging Software for Lung Diseases Market by Application
- 5.1 AI Medical Imaging Software for Lung Diseases Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Application
- 5.2.1 Global AI Medical Imaging Software for Lung Diseases Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Application (2021-2032)
- 5.2.3 Global AI Medical Imaging Software for Lung Diseases Sales Value Share by Application (2021-2032)
6 AI Medical Imaging Software for Lung Diseases Regional Value Analysis
- 6.1 Global AI Medical Imaging Software for Lung Diseases Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Region (2021-2032)
- 6.2.1 Global AI Medical Imaging Software for Lung Diseases Sales Value by Region: 2021-2026
- 6.2.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America AI Medical Imaging Software for Lung Diseases Sales Value (2021-2032)
- 6.3.2 North America AI Medical Imaging Software for Lung Diseases Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe AI Medical Imaging Software for Lung Diseases Sales Value (2021-2032)
- 6.4.2 Europe AI Medical Imaging Software for Lung Diseases Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific AI Medical Imaging Software for Lung Diseases Sales Value (2021-2032)
- 6.5.2 Asia-Pacific AI Medical Imaging Software for Lung Diseases Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America AI Medical Imaging Software for Lung Diseases Sales Value (2021-2032)
- 6.6.2 South America AI Medical Imaging Software for Lung Diseases Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa AI Medical Imaging Software for Lung Diseases Sales Value (2021-2032)
- 6.7.2 Middle East & Africa AI Medical Imaging Software for Lung Diseases Sales Value Share by Country, 2025 VS 2032
7 AI Medical Imaging Software for Lung Diseases Country-level Value Analysis
- 7.1 Global AI Medical Imaging Software for Lung Diseases Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Country (2021-2032)
- 7.2.1 Global AI Medical Imaging Software for Lung Diseases Sales Value by Country (2021-2026)
- 7.2.2 Global AI Medical Imaging Software for Lung Diseases Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.3.2 USA AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.7.2 France AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.14.2 China AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.17.2 India AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt AI Medical Imaging Software for Lung Diseases Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt AI Medical Imaging Software for Lung Diseases Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt AI Medical Imaging Software for Lung Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Riverain Technologies
- 8.1.1 Riverain Technologies Company Information
- 8.1.2 Riverain Technologies Business Overview
- 8.1.3 Riverain Technologies AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.1.4 Riverain Technologies AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.1.5 Riverain Technologies Recent Developments
- 8.2 BioMind
- 8.2.1 BioMind Company Information
- 8.2.2 BioMind Business Overview
- 8.2.3 BioMind AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.2.4 BioMind AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.2.5 BioMind Recent Developments
- 8.3 Fosun Aitrox
- 8.3.1 Fosun Aitrox Company Information
- 8.3.2 Fosun Aitrox Business Overview
- 8.3.3 Fosun Aitrox AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.3.4 Fosun Aitrox AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.3.5 Fosun Aitrox Recent Developments
- 8.4 Huiying Medical
- 8.4.1 Huiying Medical Company Information
- 8.4.2 Huiying Medical Business Overview
- 8.4.3 Huiying Medical AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.4.4 Huiying Medical AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.4.5 Huiying Medical Recent Developments
- 8.5 United-Imaging
- 8.5.1 United-Imaging Company Information
- 8.5.2 United-Imaging Business Overview
- 8.5.3 United-Imaging AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.5.4 United-Imaging AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.5.5 United-Imaging Recent Developments
- 8.6 Deepwise
- 8.6.1 Deepwise Company Information
- 8.6.2 Deepwise Business Overview
- 8.6.3 Deepwise AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.6.4 Deepwise AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.6.5 Deepwise Recent Developments
- 8.7 Shukun Technology
- 8.7.1 Shukun Technology Company Information
- 8.7.2 Shukun Technology Business Overview
- 8.7.3 Shukun Technology AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.7.4 Shukun Technology AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.7.5 Shukun Technology Recent Developments
- 8.8 VoxelCloud
- 8.8.1 VoxelCloud Company Information
- 8.8.2 VoxelCloud Business Overview
- 8.8.3 VoxelCloud AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.8.4 VoxelCloud AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.8.5 VoxelCloud Recent Developments
- 8.9 Infervision Medical
- 8.9.1 Infervision Medical Company Information
- 8.9.2 Infervision Medical Business Overview
- 8.9.3 Infervision Medical AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.9.4 Infervision Medical AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.9.5 Infervision Medical Recent Developments
- 8.10 Siemens
- 8.10.1 Siemens Company Information
- 8.10.2 Siemens Business Overview
- 8.10.3 Siemens AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.10.4 Siemens AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.10.5 Siemens Recent Developments
- 8.11 Yizhun Intelligent
- 8.11.1 Yizhun Intelligent Company Information
- 8.11.2 Yizhun Intelligent Business Overview
- 8.11.3 Yizhun Intelligent AI Medical Imaging Software for Lung Diseases Revenue and Gross Margin (2021-2026)
- 8.11.4 Yizhun Intelligent AI Medical Imaging Software for Lung Diseases Product Portfolio
- 8.11.5 Yizhun Intelligent Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst